Sterile powder for injection
Each ml contains :
Ceftizoxime sodium equivalent to ceftizoxime 1 g
Ceftizoxime is an injectable cephalosporin with a broad spectrum of activity against gram-positive and gram-negative
Ceftizoxime has a potent activity against :
Gram-positive bacteria : Streptococcus pneumoniae, Streptococcus sp. (excluding Enterococci).
Gram-negative bacteria : E. coli, Klebsiella sp, Proteus mirabilis, indole-positive Proteus sp, Haemophilus inflenze. Ceftizoxime
is also active against Citrobacter sp, Enterobacter sp, Serratia sp and anaerobes including Bacteroides sp, which are resistant to
many other cephalosporins. Its mode of action is bactericidal. It is also active against Beta lactamase producing organisms.
Septicemia, bacterial endocarditis.
Secondary infection of wounds or burns.
Bronchitis, infected bronchiectasis, secondary infections of chronic respiratory tract diseases, pneumonia, pulmonary
suppuration, pyothorax. Cholangitis, cholecystitis, peritonitis. Pyelonephritis, cystitis, prostatitis. Meningitis caused by H.
Dosage and administration :
IV injection :
Adults : usually, 0.5 – 2 g (potency)/day of ceftizoxime is administered IV in 2-4 equally divided doses,
increased to 4 g(potency)/day for severe or intractable infections, according to the age and condition of the
Children 6 months : usually, 40-80 mg (potency)/kg/day of ceftizoxime in 2-4 equally divided doses,
increased to 120 mg (potency)/kg/day for severe or intractable infections, according to the age and condition of
IM injection :
Adults : Usually, 0.5-2 g (potency)/day of ceftizoxime is administered IM in 2-4 equally divided doses, according
to the age and condition of the patient.
IV injection : reconstitute with distilled water for injection, physiological saline (isotonic sodium chloride solution) or
glucose solution and inject slowly.
IV Drip infusion : following reconstitution, dilute with IV solutions for infusion, e.g. glucose solution, electrolyte or amino
acid solutions and inject over 30-120 min.
IM injection : reconstitute with 2 ml of either distilled water for injection or 0.5% w/v lidocaine injection.
Patients with a history of shock caused by ceftizoxime sodium; a history of hypersensitivity to lidocaine or anilide-type local
anesthetics (if lidocaine is used for reconstitution before IM administration).
Careful inquiry about any form of hypersensitivity should be made to avoid shock reaction. Prior to use, skin testing is
Safety and efficacy in infants <6 months of age have not been established.
Careful administration in patients with : a history of hypersensitivity to penicillins or cephems; a personal or familial
history of some form of allergy, e.g. bronchial asthma, rash or urticaria; serious renal function disorder; as serum
ceftizoxime concentrations persist for longer periods, the dosage of the drug should be decreased and/or the
administration interval should be lengthened, proportionate to severity of renal impairment; poor oral nutrition,
parenteral nutrition, the elderly or debilitated state; careful observation is essential in these patients as vitamin K
deficiency symptoms may develop.
Use in pregnancy : safety during pregnancy has not been established.
Use in children : safety in newborns or prematures and infants < 6 months has not been established.
Adverse reactions :
Shock : adequate caution in administration should be used as shock symptoms may occur (rarely).
Hypersensitivity : if this occurs, ceftizoxime should be discontinued and appropriate measures should be taken.
Others : gastrointestinal disturbance, vitamin deficiencies and headache.
Concomitant administration with potent diuretics and nephrotoxic antibiotics may cause nephrotoxicity. Delayed excretion with
probenecid will occur.
Store in a cool (15-25C), protected from light.
Box, 2 vials @ 1 g
On medical prescription only